Experimental autoimmune uveitis (EAU) is a T cell mediated disease that specifically targets the neural retina. Although EAU can be induced by a variety of retinal antigens in many diVerent animal strains, 1 EAU in the mouse more closely resembles the pathology of a spectrum of human posterior segment intraocular inflammatory (PSII) conditions including sympathetic ophthalmia, sarcoidosis, and birdshot retinochoroidopathy.
Experimental autoimmune uveitis (EAU) is a T cell mediated disease that specifically targets the neural retina. Although EAU can be induced by a variety of retinal antigens in many diVerent animal strains, 1 EAU in the mouse more closely resembles the pathology of a spectrum of human posterior segment intraocular inflammatory (PSII) conditions including sympathetic ophthalmia, sarcoidosis, and birdshot retinochoroidopathy. [2] [3] [4] As a result of the close clinicopathological correlation of EAU in mice to human PSII, the model has been extensively used for the investigation of underlying immunological mechanisms and furthermore for the development of novel therapeutic approaches.
Mucosal administration of autoantigens results in the development of a state of peripheral immunological tolerance. 5 Mucosal tolerance induction by oral or nasal antigen administration of autoantigen eVectively prevents several experimental disease models, including experimental autoimmune encephalomyelitis (EAE), experimental myasthenia gravis (EAMG), collagen induced arthritis (CIA), insulin dependent diabetes mellitus in the NOD mouse, and EAU. [6] [7] [8] [9] [10] [11] Despite such success, the results of trials in autoimmune diseases in humans are equivocal. For example, in both multiple sclerosis and uveitis administration of bovine myelin basic protein and retinal antigens, respectively, failed to show conclusively any clinical significant improvement. 12 13 This may have been due in part to our fundamental lack of understanding of the mechanisms of tolerance with regard to induction protocol, dosage, and frequency of therapy. To date several mechanisms of mucosal tolerance induction have been proposed, including T cell anergy, 14 generation of regulatory Th3 (TGF-producing) cells, 15 or CD8+ T cells 11 16 and T cells, 17 18 all of which are dependent upon the dose and route of antigen delivery. 19 Recent data have in part shifted emphasis towards the central role of CD4+ T cells and IL-2, 20 21 including both peptide aYnity for MHC class II binding 22 as well as inherent hierarchical ability of T cell epitopes to induce tolerance. 23 With respect to CD4+ T cells, mucosal administration of autoantigen results in early activation and subsequent apoptosis of T cell populations. [24] [25] [26] [27] Studies of transgenic (Tg) mice have shown that the success of tolerance therapy is dependent upon the duration of therapy that in turn is dependent upon the precursor frequency of antigen specific T cells. 28 In both Tg OVA and AC1-9TCR Tg mice following intranasal antigen delivery early activation followed by a transient and incomplete deletion of T cells was observed. Residual T cells remained unresponsive, although in the EAE model, they produced IL-10. 28 Such results are comparable with our previous data in EAU in rat showing that, following intranasal retinal antigen delivery, lymph node cells were activated (IFN-spurt) and on further antigen challenge increased levels of apoptosis were noted within the draining lymph node.
Although the precise mechanisms of nasal tolerance induction remain undefined the specific draining lymph nodes, which directly drain the nasal or oral mucosa, do constitute a unique microenvironment, without which tolerance induction is not possible. 30 Mucosal tolerance is more eVective following nasal administration compared with oral administration of antigens at the same dose. 31 Following our previous observations of nasal tolerance with serial doses of intranasal retinal antigens in suppressing EAU in Lewis rat, 32 the aims of the present work were to better characterise the dosage and kinetics of inhibition of IRBP induced EAU via intranasal IRBP administration in a murine model.
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Materials and methods
ANTIGEN
IRBP was prepared as previously described. 34 Briefly, interphotoreceptor matrix was loaded onto a concanavalin-A (Con-A) sepharose aYnity chromatography column (Pharmacia, Sweden) and crude IRBP eluted using TRISHCl/0.15 mM NaCl/1 mM CaCl/1 mM MnCl/0.2 mM methyl-D-mannopyranoside, pH 7.5 (Sigma, UK). Further purification was achieved using a sepharose high performance chromatograph (Pharmacia) and mannose agarose aYnity column (Sigma, UK) to remove contaminating ConA. The purified IRBP was dialysed against PBS and then the concentration of the IRBP was tested by Coomassie protein assay reagent (Pierce, UK). The purified IRBP produced a single band on SDS-PAGE and was aliquoted and stored at −20°C before use.
ANIMALS
Inbred male B10RIII mice 8-12 weeks of age were obtained from the biological service unit at the medical school, University of Aberdeen. The procedures adopted conformed to the regulations of the Animal Licence Act (UK), and to the ARVO statement for the use of animals in ophthalmic and vision research.
INDUCTION OF NASAL TOLERANCE
(A) Multiple 10 day (2 week ×5) low dose tolerance induction regimen Three groups of animals (with 10 mice in each group) were administered intranasally to a total dose of 30 µg or 10 µg IRBP over 10 daily applications within 2 weeks (day −21 to −10). Controls were simultaneously treated with phosphate buVered saline (PBS). All mice were immunised on day 0 with IRBP in CFA, and with additional pertussis toxin adjuvant (PTX) (see EAU induction).
(B) 1, 2, or 3 dose tolerance induction (varying total antigen dose) Four groups of mice (eight mice in each group) were administered intranasally to a total of 120 µg IRBP per mouse over 3 days (from day −12 to −10), a total of 80 µg IRBP per mouse over 2 days (day −11 and day −10), or a single dose of 40 µg IRBP (day −10). Controls received PBS and, following intranasal administration, all animals were challenged with IRBP in CFA and PTX 9 days later.
(C) 1, 2, or 3 dose tolerance induction (total antigen dose constant)
Five groups of mice (six mice in each group) were administered intranasally to a total of 45 µg IRBP per mouse over 3 days (from day −12 to −10), a total of 45 µg IRBP per mouse over 2 days (from day −11 to day −10), a single dose of 45 µg IRBP per mouse, or PBS. All mice were then immunised with IRBP in CFA, and with additional PTX.
EAU INDUCTION AND DISEASE EVALUATION
Mice were immunised subcutaneously with 100 µg/50 µl of IRBP emulsified with an equal volume of Freund's complete adjuvant (CFA<H37R) (Difco Labs, USA). An additional intraperitoneal injection of 0.5 µg purified Bordetella pertussis toxin (PTX; strain Wellcome 28) (Speywood, UK) in 250 µl was given. At day 15 post-immunisation, mice were killed and their eyes were removed and processed as described below in each protocol. Mice from protocol (A) and (B) were killed by asphyxiation in carbon dioxide and their eyes were fixed in 2.5% buVered glutaraldehyde and embedded in resin for standard haematoxylin and eosin staining. Eyes from protocol (C) were immediately frozen in OCT and sectioned for conventional immunohistochemical staining with anti-CD45 (common leucocyte antigen, CLA, IBL-3/16, from Serotec) monoclonal antibody to detect infiltrating leucocytes within retina. The staining procedures were the same as described before. 33 Since EAU severity of both eyes from each mouse was very similar only one eye (right eye) of each mouse was graded by independent observers. The intensity of uveoretinitis was evaluated with a slightly modified version of the customised histological grading system established in this laboratory for rat EAU. 35 This grading system separately grades the degree of inflammatory cell infiltrate in various locations such as the retina, ciliary body, and anterior chamber, and the degree of standard retinal damage as evidenced by, for instance, loss of ROS, retinal folds, and retinal detachment. This allows the observers to diVerentiate between the inflammatory cell infiltrate and the structural damage to the retina/choroid since inflammatory cell infiltration does not always lead to retinal damage.
STATISTICAL ANALYSIS
Statistical analysis was performed using SPSS software. Analysis of the EAU grades (nonparametric) was performed by Mann-Whitney. A p value of <0.05 was considered statistically significant.
Results
MULTIPLE LOW DOSES OF IRBP INTRANASALLY PROTECT MICE AGAINST EAU
To investigate the eVect of multiple low doses of IRBP on the development of IRBP induced B10RIII mice EAU, animals were treated with IRBP intranasally 10 days before immunisation at doses of 1 µg and 3 µg as described in the Methods section. Control mice were given 10 doses of PBS on the same days. Nine days after completion of administration of antigen intranasally, all mice were challenged by immunising with a uveitogenic dose of IRBP. Ten animals in each group were tested. Figure  1 shows the incidence and mean severity grade (SD) of EAU. Eyes collected and processed on day 15 post-immunisation showed that mice that had received the lowest total dose of 10 µg IRBP over 10 days displayed the greatest suppression of EAU (with 4/10 incidence and severity grade of 2.4) and protection against destruction compared with the control group (with 10/10 incidence and grade of 9.4) (p = 0.001). Significant suppression of EAU was also observed in animals receiving a total dose of 30 µg IRBP over 10 days (with 7/10 incidence and EAU grade at 2.9). Thus, both the incidence and severity of EAU were reduced markedly using this regime especially at the low dose of 1 µg/day for 10 days.
ONE AND TWO, BUT NOT THREE "HIGH" CONSECUTIVE DOSES OF ANTIGEN INTRANASALLY ARE EFFECTIVE IN PREVENTING EAU
Both in the Lewis rat and, as this study shows, in murine EAU, multiple low doses of antigen by nasal administration are very eVective in protecting animals from developing EAU and the eVect is dose dependent. We therefore wished to investigate whether a single large dose of antigen could have the same eVect as multiple small doses. In this part of the study eight animals in each group were studied. As shown in Figure 2 , a single dose of 40 µg of IRBP administered 10 days before challenge significantly inhibited disease severity (incidence 2/8, grade 1.0). Two high doses (total 80 µg IRBP) on successive days were also very eVective in generating suppression of EAU (incidence 3/8, EAU grade 1.3). Increasing the dose to a total of 120 µg IRBP over 3 consecutive days failed to induce tolerance and disease suppression (incidence 6/8, grade 4.7). In this group, all mice developed severe EAU with marked target organ damage with no significant diVerence compared with the control group, which had an incidence of 7/8 and EAU grade at 5.2.
FAILURE TO PREVENT EAU WITH THE THREE DOSES OF INTRANASAL IRBP DELIVERY IS NOT RELATED TO TOTAL ANTIGEN DOSE
As our previous experiments showed one dose but not three consecutive doses of 40 µg protected against the development of target organ destruction in EAU. Experiments were then designed to determine whether protection was due to either the total amount of antigen administered or to the timing of antigen delivery. Five groups of mice (n=6 in each group) were tolerised with either two or three consecutive doses of IRBP or a single delivery of antigen. All test groups received a total dose of 45 µg IRBP/mouse or equivalent volume of PBS in controls. As shown in Figure 3 , which 
Figure 3 EVect of frequency and dose delivery during tolerance induction. EAU was significantly suppressed by a total of 45 µg IRBP in one or two doses. A total of 45 µg IRBP intranasally administered over 3 days failed to protect against IRBP induced EAU. Incidence (diseased/total mice), EAU histological grade mean and SD, and p value between the antigen and PBS tolerised groups are detailed.
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www.bjophthalmol.com group.bmj.com on June 20, 2017 -Published by http://bjo.bmj.com/ Downloaded from confirmed our previous experiments, animals that received a single intranasal antigen dose displayed greatest disease suppression (incidence 5/6, grade 2.5), with fewest signs of inflammatory cell infiltrate or target organ destruction (ROS). Animals receiving 45 µg of IRBP intranasally over 3 days were not protected (incidence 6/6, EAU grade 6.8).
INTRANASAL IRBP ADMINISTRATION INHIBITS BOTH THE INFLAMMATORY CELLS INFILTRATE AND TARGET TISSUE DAMAGE DURING EAU
Intranasal administration of retinal antigen using either the long term/low dose or the short term/high dose regimen significantly suppressed target organ (ROS) damage. Representative histological appearances shown in Figure  4 document both significant reduction in leucocytic infiltration and structural retinal damage during IRBP induced EAU in tolerised animals. Mice pretreated with PBS developed severe EAU with marked damage to target organ ROS, and leucocytic infiltration including retinal vasculitis and perivasculitis, inflammatory cell infiltration within vitreous, and all layers of retina and choroid (Fig 4c) . Frequently, the ROS layer was completely destroyed and heavily infiltrated with CD45+ leucocytes (Fig 4f) , haemorrhage, and exudate.
In comparison, animals that had received multiple low tolerogenic doses of IRBP intranasally, showed reduced infiltrating leucocyte numbers concurrent with minimal ROS loss (Fig 4a and b) . Immunohistochemical staining with CD45 in the "short term" tolerised mice showed a similar pattern of infiltrating cell distribution in vitreous, inner retinal layers but not in the target organ. In these animals, the ROS layer remained intact (Fig 4d and e) .
Discussion
Oral and nasal mucosal administration of antigen have been identified as a useful means to induce antigen specific immunological tolerance. However, tolerance induction is related to the route of antigen administration (oral, nasal, or parenteral), type of antigen (whole protein, peptide, or altered peptide), and timing with regard to disease onset. 5 The possibility of enhancing rather than inhibiting immunity is also raised depending on the conditions prevailing while antigen is administered. The quantity of the administered antigen usually influences the tolerogenic eVect, although no criterion of dose dependent eVect of mucosal tolerance so far has been established in any animal or human trials. Our results show that intranasal inoculation with IRBP had diVerent eVects on murine IRBP induced EAU according to both dose and frequency of administration. Maximal inhibition of both the incidence and severity of EAU in IRBP induced B10RIII mice was noticed in those mice pretreated with multiple small doses (total 10 µg) of IRBP. This is in agreement with our previous data from the rat EAU model that showed suppression of EAU can be achieved by administering multiple low doses of retinal extract, S-Ag, or IRBP via the nasorespiratory tract. 26 35 However, Tsitoura et al reported that low doses such as 0.1 µg administered intranasally over 3 days failed to downregulate T cell responsiveness. 36 The importance of dose and dosing regimen is also recognised in oral tolerance 21 : feeding the antigen three times did not protect the mice against EAU while multiple feedings (five times) protected against disease induction. These results may indicate that in a low dose pretreatment regimen (10 days in our experiment), the dosage level is critical to achieve protection. The results of this and other studies suggest that long term/low dose regimen of intranasal administration of autoantigen is potentially a safe and eVective route for antigen based immunotherapy for autoimmune disease.
With respect to manipulating dose, we observed that a single or at most two high doses of antigen were protective. This is in agreement with a study 37 in a spontaneous insulin dependent diabetes murine model which showed that a single intranasal administration of 50 µg GAD65 peptides induces a Th2 cell response that inhibited the spontaneous development of autoreactive Th1 responses and the progression of cell autoimmunity in NOD mice. However, our results also showed that multiple high doses (three doses) were ineVective in protecting against EAU. Moreover, it was the single administration of 45 µg, but not a total amount of 45 µg (15 µg per day) over 3 days that achieved protection in mice. One interpretation, therefore, is that not only the dose, but also the frequency of administration is critical to nasal mucosal tolerance induction. The therapeutic window is therefore small when using higher doses of antigen and may thus be a less successful approach when translated into clinical use.
The mechanisms by which mucosal tolerance is mediated are only partly understood. It is suggested that diVerent mechanisms operate at diVerent doses both in oral 38 and nasal tolerance. 39 Low dose tolerance is mediated by active suppression, while high doses of antigen tend to induce anergy or clonal deletion. Recently, controversial results regarding the function of Th3 T cells in mucosal tolerance have been reported. Baggi et al suggest that Th3 cells were not involved in oral tolerance induction, 40 although this is in disagreement with other reports that show an induction of antigen specific TGF-producing T cells are involved in disease suppression. 41 42 There is further evidence from clinical observations in patients with multiple sclerosis that antigen specific TGF-1 secreting T cells represent a distinct lineage of T cells that localise to the target organ and then suppress inflammation in the local microenvironment. 43 In the present study, we attempted to use flow cytometry to detect the changes of activation markers on CD4 and CD8 T cells in the draining lymph nodes after a single intranasal antigen administration. A decrease in the proportion of CD4+CD62L+ and CD8+CD62+ (CD62L, L-selectin) cells in the draining lymph node was frequently detected hours and days after intranasal administered of antigens from regional lymph node (data not shown). CD62L downregulation, however, was not consistent and was transient. Herbelin et al 44 have shown that TCR + CD4+ thymocytes expressing L-selectin mediate active tolerance in the nonobese diabetic mouse. We were unable to determine consistent changes in CD62L expression following a single dose and found no relation with generation of regulatory CD4+CD45RB low CD38+ T cells. 45 It is generally believed that there is reciprocal inhibition of Th1 and Th2 response, and Th2 response exerts protective functions in Th1 mediated experimental models of autoimmune disease as both IL-4 and IL-10 are required for the induction of mucosal tolerance. 46 Our previous investigation in the rat EAU model with a long term regimen has demonstrated a reduced percentage of IFN-+ macrophages and CD4+ T cells with an increased percentage of IL-4+ or IL-10+ CD4+ T cells. 29 Moreover, previous work has also shown transient T cell activation in the draining lymph nodes following the intranasal administration of retinal antigens, and that suppression of systemic Th1 responses is mediated by spleen regulatory cells during low dose tolerance therapy. 26 Interestingly, a single high dose of antigen administered intranasally led to the induction of Th2 responses in the IDDM mouse model, and the adoptive co-transfer of splenic T cells from GAD64 peptide treated mice protects recipient NOD-scid/scid mice from IDDM. 46 The two studies, by using diVerent dose regimens for nasal tolerance in diVerent autoimmune disease models, both showed the generation of Th2 cells and disease protection following transfer of splenocytes. One theory, therefore, is that multiple mechanisms are operative during high dose/short term and long term/low dose regimens so as to prevent the host from generating proinflammatory immunity to ingested antigen.
In conclusion, our results suggest that the eVect of intranasal administration of autoantigens against autoimmune diseases is both dose and frequency dependent, and that successful tolerance induction is dependent upon route, antigen, species, and strain. These findings have important implications for the therapeutic applications of nasal tolerance in the clinic.
